The quarter cleared expectations, mainly on adjusted earnings. Adjusted diluted EPS was $0.91 versus a published consensus near $0.66, while revenue of $183.9 million was only modestly above estimates near $181.9 million. That makes this a genuine earnings beat, but not a broad-based upside surprise. GAAP diluted EPS was $0.67, up from $0.64 a year ago, while adjusted net income was essentially flat at $40.8 million versus $40.9 million. (Financial Highlights)
| Metric | Q2 2026 | Q2 2025 | Change | Expectation |
|---|---|---|---|---|
| Net revenue | $183.9M | $174.4M | +5% | ~$181.9M |
| GAAP diluted EPS | $0.67 | $0.64 | +5% | — |
| Adjusted diluted EPS | $0.91 | $0.85 | +7% | ~$0.66 |
| Gross margin | 50.8% | 49.6% | +120 bps | — |
| Operating income | $39.7M | $42.2M | -6% | — |
New launches are doing the heavy lifting while established products weaken. Ipratropium bromide contributed $8.4 million after its April launch, and other products rose 25% to $66.2 million, supported by iron sucrose and teriparatide. That growth offset declines in BAQSIMI, Primatene MIST, epinephrine, and especially glucagon, which fell 42% to $11.9 million. BAQSIMI revenue also fell 3% because lower pricing and gross-to-net deductions more than offset volume growth. (Second Quarter Results)
The margin improvement is real, but underlying operating leverage was not. Gross margin expanded to 50.8% from 49.6%, helped by the newer, higher-margin products. However, selling and marketing, general and administrative, and R&D expenses rose 30%, 30%, and 10%, respectively, pushing operating income down despite higher revenue. The adjusted-EPS beat therefore looks more like a mix of favorable gross profit and below-operating-line items than a clean acceleration in core profitability. (Table I; Table III)
A known cash obligation will absorb a meaningful part of the balance-sheet improvement. Amphastar generated $99.2 million of operating cash flow in the first half and ended June with $223.6 million in cash, but it owes Lilly $100.0 million in the third quarter after reaching the first BAQSIMI sales milestone. The filing also shows total liabilities rising to $975.6 million from $840.5 million at year-end, so the quarter's beat does not materially remove the company's financial commitments. (Cash Flow statement; Table II)
Net read: a beat, but one that is narrower than the headline EPS number suggests. The market received better-than-expected adjusted earnings and slightly better revenue, with new products improving mix and margins. Against that, pricing pressure, competitive losses in glucagon and epinephrine, sharply higher operating costs, and the upcoming Lilly payment keep the result from signaling a clean step-up in the established business. (Financial Highlights; Second Quarter Results)
Read the original 8-K on SEC EDGAR ↗